This is a Phase I randomized double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD9742 in healthy male and female Japanese subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
35
Research Site
Glendale, California, United States
Safety variables (adverse events, vital signs, physical examinations, clinical laboratory assessments, 12-lead ECG, digital ECG, telemetry)
Time frame: collected prior to treatment, during treatment and follow-up for a total of 18-22 days
Characterize the Pharmacokinetics of AZD9742 in blood and urine
Time frame: PK-sampling during 14 pre-defined study days for PK profiling
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.